IGM Biosciences IGMS, a clinical-stage company, is developing a pipeline of Immunoglobin M (IgM) antibody-based candidates to treat patients with cancer and autoimmune and inflammatory diseases. The ...

IGM Biosciences, Inc.’s IGMS share price nearly doubled on Tuesday, after the company announced that it has entered into an exclusive partnership with Sanofi SNY to create, develop and commercialize ...

Is IGM Biosciences, Inc. (NASDAQ:IGMS) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top ...

The average one-year price target for IGM Biosciences (NasdaqGS:IGMS) has been revised to 21.01 / share. This is an increase of 9.28% from the prior estimate of 19.23 dated January 16, 2024. The price ...